Correct - there are only a handful left to clear - not totally unexpected given the market conditions and given the IPO went to some of the "wrong hands" (not ppl interested in the potential of the company/experienced in biotech) then missed the unrealistic expectations pitched to them (combo of market conditions and some other factors). Top 50 is now up to ~70m/70%+ & what's becoming a tight register to build an Market cap more reflective of the potential & progress to date. I expect a material rerate (to the upside) to something more sensible shortly.
"We have reviewed the top 50 as at the 26th of April 2018 and the directors holdings have remained consistent. We note some additional holders on the Top 20 of the register since the IPO.